3 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Dermatitis, Atopic, Eczema | Phase 3 | Active not recruiting | Almirall, S.A. | 520 | 2024-07-03 | 2026-04-21 |
| A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo, Topical Corticosteroid (TCS) - Atopic Dermatitis, Eczema | Phase 3 | Active not recruiting | Eli Lilly and Company | 377 | 2022-10-18 | 2026-07-30 |
| The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants EpiCeram - Eczema, Asthma | Phase 3 | Active not recruiting | University of Melbourne | 760 | 2018-03-06 | 2023-05-10 |
Dermatitis, Atopic (2) · Asthma (1) · Dermatitis (1) · Food Hypersensitivity (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1)
Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Skin and Connective Tissue Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Skin Diseases (2) · Skin Diseases, Eczematous (2) · Skin Diseases, Genetic (2) · Bronchial Diseases (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Respiratory Hypersensitivity (1) · Respiratory Tract Diseases (1)
lebrikizumab (2) · Adrenal Cortex Hormones (1) · EpiCeram (1)
Almirall, S.A. (1) · Eli Lilly and Company (1) · University of Melbourne (1)
Australia (2) · Spain (2) · Argentina (1) · Brazil (1) · Canada (1) · Czechia (1) · Germany (1) · Japan (1) · Mexico (1) · Poland (1) · Taiwan (1) · United States (1)
2023 (1)